Geovax receives notice of allowance for hiv vaccine patent

Atlanta, ga, oct. 05, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the u.s. patent and trademark office has issued a notice of allowance for patent application no. 17/409,574 titled “multivalent hiv vaccine boost compositions and methods of use.” the allowed claims generally cover a priming vaccination with a dna vector encoding multiple hiv antigens in virus-like particles (vlps), followed by a boost vaccination with geovax's vector platform for expressing hiv-1 antigens in vlps utilizing an mva viral vector.
GOVX Ratings Summary
GOVX Quant Ranking